Bevacizumab (trade name, AVASTIN®, Genentech/Roche), a monoclonal antibody raised against human vascular endothelial growth factor A (VEGFA) inhibits the VEGFA signaling pathway, which is involved in tumor-derived angiogenesis [22]. Here, VEGFA is linked to neoplasm.